132 related articles for article (PubMed ID: 15587764)
21. [Breakthrough in the treatment of osteoporosis].
Brixen KT; Langdahl BL; Christensen PM; Ejersted CA
Ugeskr Laeger; 2004 Aug; 166(32):2649. PubMed ID: 15347164
[No Abstract] [Full Text] [Related]
22. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
23. [Teriparatide--new value in osteoporosis treatment: treatment guidelines].
Korsić M; Kastelan D
Reumatizam; 2006; 53(2):77-81. PubMed ID: 17580560
[TBL] [Abstract][Full Text] [Related]
24. Strontium ranelate for osteoporosis?
Drug Ther Bull; 2006 Apr; 44(4):29-32. PubMed ID: 16617933
[TBL] [Abstract][Full Text] [Related]
25. Teriparatide. LY 333334, MN 10T, parathyroid hormone (1-34), parathyroid hormone (1-34)-Asahi, parathyroid hormone (1-34)-Eli Lilly, parathyroid hormone (1-34)-Rhône-Poulenc Rorer, teriparatide acetate, hPTH 1-34, Parathar.
Drugs R D; 1999 Mar; 1(3):222-4. PubMed ID: 10566031
[No Abstract] [Full Text] [Related]
26. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.
Miller RG
Geriatrics; 2006 Jan; 61(1):24-30. PubMed ID: 16405361
[TBL] [Abstract][Full Text] [Related]
27. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.
Uusi-Rasi K; Semanick LM; Zanchetta JR; Bogado CE; Eriksen EF; Sato M; Beck TJ
Bone; 2005 Jun; 36(6):948-58. PubMed ID: 15878318
[TBL] [Abstract][Full Text] [Related]
28. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Ballaouri I; Efstathiadou Z; Kita M; Avramidis A
Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
[TBL] [Abstract][Full Text] [Related]
29. Postmenopausal women with osteoporosis: experience when treated with teriparatide in clinical practice.
Ish-Shalom S; Dumitrache C; El-Husseini TF; Hussein A; Barker C; Pavo I
Curr Med Res Opin; 2011 Feb; 27(2):343-53. PubMed ID: 21166609
[TBL] [Abstract][Full Text] [Related]
30. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
31. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Koukoulis G; Kita M; Avramidis A
Horm Metab Res; 2008 Apr; 40(4):281-5. PubMed ID: 18275008
[TBL] [Abstract][Full Text] [Related]
32. New drug builds bone.
Harv Womens Health Watch; 2001 Jul; 8(11):2. PubMed ID: 11511464
[No Abstract] [Full Text] [Related]
33. New osteoporosis strategy: boosting bone growth.
Johns Hopkins Med Lett Health After 50; 2004 Apr; 16(2):4--5. PubMed ID: 15088565
[No Abstract] [Full Text] [Related]
34. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
Epstein S
Clin Ther; 2006 Feb; 28(2):151-73. PubMed ID: 16678639
[TBL] [Abstract][Full Text] [Related]
35. Parathyroid hormone: new drug. Osteoporosis: just a teriparatide me-too.
Prescrire Int; 2008 Jun; 17(95):102. PubMed ID: 18623910
[TBL] [Abstract][Full Text] [Related]
36. Bone anabolic agents: the unanswered queries.
Adami S; Viapiana O; Gatti D
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):257-9. PubMed ID: 15228496
[No Abstract] [Full Text] [Related]
37. Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study.
Jakob F; Oertel H; Langdahl B; Ljunggren O; Barrett A; Karras D; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Barker C; Lems WF; Marin F
Eur J Endocrinol; 2012 Jan; 166(1):87-97. PubMed ID: 22048967
[TBL] [Abstract][Full Text] [Related]
38. The use of bisphosphonates in osteoporosis.
Fleisch H
Br J Clin Pract; 1994; 48(6):323-6. PubMed ID: 7848797
[TBL] [Abstract][Full Text] [Related]
39. [New medication for osteoporosis. To further increase instead of braking reduction].
MMW Fortschr Med; 2003 Oct; 145(44):44. PubMed ID: 14655508
[No Abstract] [Full Text] [Related]
40. [Bone anabolic drug for severe osteoporosis. Forsteo available on the German market].
Krankenpfl J; 2003; 41(10-12):240. PubMed ID: 14746212
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
